Drug news
Cell Therapeutics acquires world rights to pancritinib for Myelofibrosis
Cell Therapeutics has acquired a worldwide licence from Singapore-based S*Bio to develop and manufacture pancritinib, an oral once daily, tyrosine kinase inhibitor with dual activity against JAK 2 (Janus Associated Kinase 2) and FMS-like tyrosine kinase 3 (FLT 3). Pacritinib is in Phase II clinical trials for Myelofibrosis with a Phase III trial planned. The drug has Orphan designation in both the USA and EU.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.